In Parkinson's disease (PD), clinical observations and some studies suggest that depression and anxiety are linked to motor fluctuations. We studied prospectively 10 patients with advanced PD just before initiation of intrajejunal levodopa/carbidopa therapy, and after 1 and 3 months of regular treatment. Motor symptoms, motor fluctuations, non-motor symptoms, quality of sleep, symptoms of depression and anxiety were evaluated with the appropriate scales. As expected, motor symptoms and motor fluctuations improved considerably. Non-motor symptoms, quality of sleep and depression also improved significantly. However, anxiety score remained unchanged during the study. Our data in a small numbers of patients indicate that all aspects of mental and psychic symptoms are not alleviated within a short period of reduction of motor fluctuations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s13760-015-0497-x | DOI Listing |
J Neural Eng
January 2025
University of Pittsburgh, 1622 Locust St, Pittsburgh, Pennsylvania, 15219, UNITED STATES.
Real-world implementation of brain-computer interfaces (BCI) for continuous control of devices should ideally rely on fully asynchronous decoding approaches. That is, the decoding algorithm should continuously update its output by estimating the user's intended actions from real-time neural activity, without the need for any temporal alignment to an external cue. This kind of open-ended temporal flexibility is necessary to achieve naturalistic and intuitive control, but presents a challenge: how do we know when it is appropriate to decode anything at all? Activity in motor cortex is dynamic and modulates with many different types of actions (proximal arm control, hand control, speech, etc.
View Article and Find Full Text PDFPLoS One
January 2025
Institute of Psychiatry, Psychology & Neuroscience at King's College London, London, United Kingdom.
Fluctuation-related pain (FRP) affects more than one third of people with Parkinson's disease (PwP, PD) and has a harmful effect on health-related quality of life (HRQoL), but often remains under-reported by patients and neglected by clinicians. The National Institute for Health and Care Excellence (NICE) recommends The Parkinson KinetiGraphTM (the PKGTM) for remote monitoring of motor symptoms. We investigated potential links between the PKGTM-obtained parameters and clinical rating scores for FRP in PwP in an exploratory, cross-sectional analysis of two prospective studies: "The Non-motor International Longitudinal, Real-Life Study in PD-NILS" and "An observational-based registry of baseline PKG™ in PD-PKGReg".
View Article and Find Full Text PDFBiochem Biophys Res Commun
January 2025
Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; World Premier International Research Center Initiative, Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan. Electronic address:
Parkinson's disease (PD) is a neurodegenerative disease primarily affecting the central nervous system and impacting both the motor system and non-motor systems. Although administration of L-DOPA is effective, it is not a fundamental treatment and has side effects such as diurnal fluctuation and dyskinesia, highlighting the need for new treatment methods. There is a growing interest in dopaminergic neuron transplantation as a potential treatment.
View Article and Find Full Text PDFSleep
January 2025
Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO USA.
Study Objectives: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) may improve sleep dysfunction, a common non-motor symptom of Parkinson disease (PD). Improvement in motor symptoms correlates with DBS-suppressed local field potential (LFP) activity, particularly in the beta frequency (13 - 30 Hz). Although well-characterized in the short term, little is known about the innate progression of these oscillations across the sleep-wake cycle.
View Article and Find Full Text PDFEur J Neurol
January 2025
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Background: Catechol-O-methyl transferase (COMT) inhibitors are routinely used to manage motor fluctuations in Parkinson's disease (PD). We assessed the effect of opicapone on motor symptom severity in levodopa-treated patients without motor complications.
Methods: This was a randomized, double-blind, 24-week, placebo-controlled study of opicapone 50 mg as adjunct to levodopa (NCT04978597).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!